Press Releases Ypsomed Group

Burgdorf - ln connection with allegations that the OptiClik pen could be infringing a US patent, Ypsomed has commissioned both an internal and an external expert opinion, both of which have concluded that the OptiClik pen device made by the company does not infringe the patent claims of Novo Nordisk. Ypsomed therefore considers the accusations made by Novo Nordisk to be unjustified. The patent infringement suit has no effect on production of the OptiClik pen or on the further expansion of production capacities at Ypsomed.

Go Back